The healthcare provider and individual may decide to use an oral lead-in with oral cabotegravir prior to the initiation of Apretude to assess the tolerability of cabotegravir or the healthcare provider and individual may proceed directly to injection of Apretude without the use of an oral lead-in. No safety and efficacy data are available for use of Apretude without an oral lead-in. However, in HIV-1 treatment clinical trials, data show that an oral lead-in is not needed to ensure adequate plasma cabotegravir exposure upon initiation of injections and that the safety and efficacy results of Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension) were similar when administered with and without an oral lead-in. If an individual plans to miss a scheduled every-2-month continuation injection visit by more than 7 days, take daily oral cabotegravir for a duration of up to 2 months to replace 1 missed scheduled every-2-month injection. The recommended oral daily dose is one 30-mg tablet of oral cabotegravir.